Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis

BACKGROUND: The prognostic significance of TP53 concurrent mutations in patients with epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)- mutated advanced non–small-cell lung cancer (NSCLC) who received EGFR-tyrosine kinase inhibitors (TKIs) or ALK-TKIs based targeted thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Kang, Hou, Helei, Liang, Yu, Zhang, Xiaochun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164297/
https://www.ncbi.nlm.nih.gov/pubmed/32299384
http://dx.doi.org/10.1186/s12885-020-06805-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164297/
https://www.ncbi.nlm.nih.gov/pubmed/32299384
http://dx.doi.org/10.1186/s12885-020-06805-5

Ejemplares similares